Our studies and those of our peers have shown that CXCL12 expression is markedly increased in the DRG after neuropathic pain induced by nerve injury or a chemotherapeutic agent and that inhibiting CXCR4, a CXCL12 receptor, attenuates these abnormal pain behaviours31–33. The gene discussed is CXCL12; the disease is injury.